NasdaqHealth CareHealth Care ServicesS&P MidCap 400
$16.01
+0.14 (+0.88%)
Close of Nov 06, 2026 · end-of-day data
SHC 8-K filings in 2024
Every material Form 8-K Sotera Health filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sotera Health reported third-quarter 2024 net revenues of $285 million, up 8.5% from a year earlier, and net income of $17 million, or $0.06 per diluted share, compared with a net loss of $14 million a year earlier. The company reaffirmed its 2024 net revenue and Adjusted EBITDA growth outlook, but lowered its capital expenditure forecast to $175 million to $185 million.
Q3 2024 net revenues were $285 million, up 8.5%; Adjusted EBITDA was $146 million, up 9.0%
Q3 2024 net income was $17 million ($0.06 per diluted share), versus a net loss of $14 million ($0.05 per share) in Q3 2023
2024 outlook for net revenue and Adjusted EBITDA growth of 4.0% to 6.0% was reaffirmed; Adjusted EPS range of $0.67 to $0.75 was also reaffirmed
Capital expenditure guidance was updated to $175 million to $185 million, from $205 million to $225 million previously
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sotera Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →